# A Bioequivalence Study of APX001 High-load and Low-load Tablets

> **NCT05491733** · PHASE1 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 18 (actual)

## Conditions studied

- Invasive Fungal Infections

## Interventions

- **DRUG:** APX001
- **DRUG:** APX001A

## Key facts

- **NCT ID:** NCT05491733
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-02
- **Primary completion:** 2021-05-13
- **Final completion:** 2021-06-23
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491733, "A Bioequivalence Study of APX001 High-load and Low-load Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05491733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*